Two ASX healthcare stocks, investors should keep an eye upon
The following ASX healthcare stocks are gaining momentum as key clinical and regulatory milestones along with upcoming commercial catalysts position them for substantial upside.
Proteomics International Laboratories Limited (ASX: PIQ)
Proteomics International Laboratories Limited surged more than 14% on Monday after announcing that its US Reference Laboratory has received CAP accreditation which is a key regulatory milestone that accelerates commercialisation efforts in the United States.
The company also confirmed the successful installation and commissioning of a new precision diagnostics mass spectrometry platform.
Cash receipts from customers for the September quarter amounted to $1.86 million which was a sharp increase from $0.20 million in the June quarter and was mainly driven by a non-recurring $1.71 million receipt linked to the WA Proteomics Facility partnership.
As at 30 September 2025, the company held cash reserves of $10 million which strengthened after receiving a Research and Development tax incentive rebate of approximately $2.2 million in November.
With CAP accreditation now complementing its existing CLIA certification, Proteomics International is implementing testing protocols ahead of the planned United States launch of PromarkerEso in 2026.
Nyrada Inc (ASX: NYR)
Nyrada Inc rose more than 19% on Monday helped by the fact that its Phase IIa clinical trial of Xolatryp is on track to commence in March 2026.
The company has successfully completed its Phase I clinical trial which confirmed a strong safety profile with no serious adverse events reported across all participant cohorts.
Nyrada closed the September 2025 quarter with a cash balance of $7.92 million compared with $2.93 million at the end of June reflecting the successful completion of an $8.25 million capital raise in August 2025.
Quarterly operating cash outflows amounted to $2.73 million and were mainly driven by research and development expenditure which is consistent with a company at this stage of clinical development.
Positive outcomes from the Phase IIa trial would mark a major value inflection point as it would represent the first demonstration of clinical efficacy in humans for Xolatryp and Nyrada is positioning itself as a differentiated cardioprotection and neuroprotection biotechnology company ahead of key clinical milestones in 2026.
(Source: Company Reports)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
